All Updates

All Updates

icon
Filter
Partnerships
Optimi Health and Mind Medicine Australia launch OptiMed for psychiatrists
Psychedelic Medicine
Jun 27, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Psychedelic Medicine

Psychedelic Medicine

Jun 27, 2024

Optimi Health and Mind Medicine Australia launch OptiMed for psychiatrists

Partnerships

  • Canada-based psychedelic drug manufacturer Optimi Health has partnered with Mind Medicine Australia to launch a resource platform for Australian psychiatrists called "OptiMed."

  • The OptiMed Prescriber Portal offers comprehensive resources, secure communication tools, multimedia, and regulatory guidance on psilocybin and MDMA drug candidates.

  • Supported by Optimi and Mind Medicine Australia staff, the platform aims to facilitate the safe and effective prescription of psychedelic medicines through the Authorised Prescriber Scheme in Australia. It is exclusive to Australian psychiatrists, with plans for expansion to other countries as local regulations permit.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.